Literature DB >> 23550703

Global analysis of phosphorylation of tau by the checkpoint kinases Chk1 and Chk2 in vitro.

Jhoana Mendoza1, Michiko Sekiya, Taizo Taniguchi, Koichi M Iijima, Rong Wang, Kanae Ando.   

Abstract

Hyperphosphorylation of microtubule-associated protein tau is thought to contribute to Alzheimer's disease (AD) pathogenesis. We previously showed that DNA damage-activated cell cycle checkpoint kinases Chk1 and Chk2 phosphorylate tau at an AD-related site and enhance tau toxicity, suggesting potential roles of these kinases in AD. The purpose of this study is to systematically identify which sites in tau are directly phosphorylated by Chk1 and Chk2. Using recombinant human tau phosphorylated by Chk1 and Chk2 in vitro, we first analyzed tau phosphorylation at the AD-related sites by Western blot with phospho-tau-specific antibodies. Second, to globally identify phosphorylated sites in tau, liquid chromatography-tandem mass spectrometry (LC-MS(3)) was employed. These systematic analyses identified a total of 27 Ser/Thr residues as Chk1- or Chk2- target sites. None of them were proline-directed kinase targets. Many of these sites are located within the microtubule-binding domain and C-terminal domain, whose phosphorylation has been shown to reduce tau binding to microtubules and/or has been implicated in tau toxicity. Among these 27 sites, 13 sites have been identified to be phosphorylated in AD brains. Since DNA damage is accumulated in diseased brains, Chk1 and Chk2 may be involved in tau phosphorylation and toxicity in AD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23550703      PMCID: PMC3757556          DOI: 10.1021/pr400008f

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  86 in total

1.  Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation.

Authors:  Fei Liu; Bin Li; E-Jan Tung; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  Eur J Neurosci       Date:  2007-12-04       Impact factor: 3.386

Review 2.  The tau of MARK: a polarized view of the cytoskeleton.

Authors:  Dorthe Matenia; Eva-Maria Mandelkow
Journal:  Trends Biochem Sci       Date:  2009-06-24       Impact factor: 13.807

Review 3.  Biochemistry of Tau in Alzheimer's disease and related neurological disorders.

Authors:  Nicolas Sergeant; Alexis Bretteville; Malika Hamdane; Marie-Laure Caillet-Boudin; Pierre Grognet; Stephanie Bombois; David Blum; André Delacourte; Florence Pasquier; Eugeen Vanmechelen; Susanna Schraen-Maschke; Luc Buée
Journal:  Expert Rev Proteomics       Date:  2008-04       Impact factor: 3.940

Review 4.  The DNA-damage response in human biology and disease.

Authors:  Stephen P Jackson; Jiri Bartek
Journal:  Nature       Date:  2009-10-22       Impact factor: 49.962

Review 5.  Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Curr Opin Cell Biol       Date:  2009-02-21       Impact factor: 8.382

6.  Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ.

Authors:  H Lassmann; C Bancher; H Breitschopf; J Wegiel; M Bobinski; K Jellinger; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 7.  CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

Authors:  Laurent Antoni; Nayanta Sodha; Ian Collins; Michelle D Garrett
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

Review 8.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders.

Authors:  Carlo Ballatore; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2007-09       Impact factor: 34.870

Review 9.  Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.

Authors:  Diane P Hanger; Brian H Anderton; Wendy Noble
Journal:  Trends Mol Med       Date:  2009-02-24       Impact factor: 11.951

10.  Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.

Authors:  Diane P Hanger; Helen L Byers; Selina Wray; Kit-Yi Leung; Malcolm J Saxton; Anjan Seereeram; C Hugh Reynolds; Malcolm A Ward; Brian H Anderton
Journal:  J Biol Chem       Date:  2007-06-11       Impact factor: 5.157

View more
  14 in total

Review 1.  WNT/β-catenin Pathway: a Possible Link Between Hypertension and Alzheimer's Disease.

Authors:  Alexandre Vallée; Jean-Noël Vallée; Yves Lecarpentier
Journal:  Curr Hypertens Rep       Date:  2022-07-05       Impact factor: 4.592

2.  Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.

Authors:  Jangampalli Adi Pradeepkiran; Manne Munikumar; Arubala P Reddy; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2021-12-27       Impact factor: 5.121

Review 3.  The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease.

Authors:  Zhenzhen Liu; Tao Li; Ping Li; Nannan Wei; Zhiquan Zhao; Huimin Liang; Xinying Ji; Wenwu Chen; Mengzhou Xue; Jianshe Wei
Journal:  Oxid Med Cell Longev       Date:  2015-06-15       Impact factor: 6.543

Review 4.  CHK2 kinase in the DNA damage response and beyond.

Authors:  Laura Zannini; Domenico Delia; Giacomo Buscemi
Journal:  J Mol Cell Biol       Date:  2014-11-17       Impact factor: 6.216

Review 5.  Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma.

Authors:  Alexandre Vallée; Yves Lecarpentier
Journal:  Front Neurosci       Date:  2016-10-19       Impact factor: 4.677

6.  A New Quantitative Cell-Based Assay Reveals Unexpected Microtubule Stabilizing Activity of Certain Kinase Inhibitors, Clinically Approved or in the Process of Approval.

Authors:  Sacnicte Ramirez-Rios; Sophie Michallet; Leticia Peris; Caroline Barette; Clotilde Rabat; Yangbo Feng; Marie-Odile Fauvarque; Annie Andrieux; Karin Sadoul; Laurence Lafanechère
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

7.  Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.

Authors:  Yuxing Xia; Stefan Prokop; Kimberly-Marie M Gorion; Justin D Kim; Zachary A Sorrentino; Brach M Bell; Alyssa N Manaois; Paramita Chakrabarty; Peter Davies; Benoit I Giasson
Journal:  Acta Neuropathol Commun       Date:  2020-06-22       Impact factor: 7.801

8.  Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer's Disease.

Authors:  Jangampalli Adi Pradeepkiran; P Hemachandra Reddy
Journal:  Cells       Date:  2019-03-19       Impact factor: 6.600

Review 9.  Tau at the interface between neurodegeneration and neuroinflammation.

Authors:  Alessandro Didonna
Journal:  Genes Immun       Date:  2020-10-03       Impact factor: 2.676

Review 10.  The role of Wnt signaling in the development of Alzheimer's disease: a potential therapeutic target?

Authors:  Wenbin Wan; Shijin Xia; Bill Kalionis; Lumei Liu; Yaming Li
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.